Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma.

Heinz Ludwig, MD, Zdenek Adam, MD, Elena Tóthová, MD, Roman Hajek, MD, Boris Labar, MD, PhD, Miklós Egyed, MD, PhD, Ivan Spicka, MD, Johannes Drach, MD, Heinz Gisslinger, MD, Ingrid Kuhn, MD, Niklas Zojer, MD, Zoran Birovljev, Axel Hinke, PhD

Blood (2009) 114 (22): 2891.

https://doi.org/10.1182/blood.V114.22.2891.2891

Published: 2009

Journal Articles

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

Heinz Ludwig, Roman Hajek, Elena Tóthová, Johannes Drach, Zdenek Adam, Boris Labar, Miklós Egyed, Ivan Spicka, Heinz Gisslinger, Richard Greil, Ingrid Kuhn, Niklas Zojer, Axel Hinke

Blood (2009) 113 (15): 3435–3442.

https://doi.org/10.1182/blood-2008-07-169565

Published: 2009

Journal Articles

Double Transplantation with Melphalan (200 mg/m 2 ) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma

Heinz Ludwig, MD, Ivan Spicka, MD, Werner Linkesch, MD, Richard Greil, Hedwig Kasparu, MD, Eberhard Gunsilius, MD, Josef Thaler, MD, Johannes Drach, MD, Ingrid Kuhn, MD, Adalbert Weiβmann, MD, Axel Hinke, PhD

Blood (2008) 112 (11): 3317.

https://doi.org/10.1182/blood.V112.11.3317.3317

Published: 2008

Journal Articles

Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.

Heinz Ludwig, MD, Elena Tothova, MD, Roman Hajek, MD, Johannes Drach, MD, Zdenek Adam, MD, Boris Labar, MD, Miklós Egyed, MD, Ivan Spicka, MD, Heinz Gisslinger, MD, Ingrid Kuhn, MD, Axel Hinke, PhD

Blood (2007) 110 (11): 529.

https://doi.org/10.1182/blood.V110.11.529.529

Published: 2007

Journal Articles

Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m 2 ) and Triple T with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma (An Interim Analysis).

Heinz Ludwig, MD, Werner Linkesch, MD, Hedwig Kasparu, MD, Otto Krieger, MD, Ivan Spicka, MD, Gunther Gastl, MD, Richard Greil, MD, Johannes Drach, MD, Josef Thaler, MD, Ingrid Kuhn, Niklas Zojer, MD, Axel Hinke, PhD

Blood (2006) 108 (11): 3083.

https://doi.org/10.1182/blood.V108.11.3083.3083

Published: 2006

Journal Articles

Thalidomide-Dexamethasone Versus Melphalan-Prednisolone as First Line Treatment in Elderly Patients with Multiple Myeloma: An Interim Analysis.

Heinz Ludwig, MD, Johannes Drach, MD, Elena Tóthová, MD, Heinz Gisslinger, MD, Werner Linkesch, MD, Boris Jaksic, MD, Michael Fridik, MD, Josef Thaler, MD, Alois Lang, MD, Roman Hajek, MD, Niklas Zojer, MD, Richard Greil, MD, Ingrid Kuhn, Axel Hinke, Boris Labar, MD

Blood (2005) 106 (11): 782.

https://doi.org/10.1182/blood.V106.11.782.782

Published: 2005

Journal Articles

Elevated Serum Thymidine Kinase Levels Identify a Subgroup at High Risk of Disease Progression in Early, Nonsmoldering Chronic Lymphocytic Leukemia

Michael Hallek, Irmgard Langenmayer, Christoph Nerl, Wolfgang Knauf, Hermann Dietzfelbinger, Dagmar Adorf, Marianne Ostwald, Raymonde Busch, Ingrid Kuhn-Hallek, Eckhard Thiel, Bertold Emmerich

Blood (1999) 93 (5): 1732–1737.

https://doi.org/10.1182/blood.V93.5.1732

Published: 1999

NARROW

Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma.

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

Double Transplantation with Melphalan (200 mg/m 2 ) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma

Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.

Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m 2 ) and Triple T with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma (An Interim Analysis).

Thalidomide-Dexamethasone Versus Melphalan-Prednisolone as First Line Treatment in Elderly Patients with Multiple Myeloma: An Interim Analysis.

Elevated Serum Thymidine Kinase Levels Identify a Subgroup at High Risk of Disease Progression in Early, Nonsmoldering Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma.

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

Double Transplantation with Melphalan (200 mg/m 2 ) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma

Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.

Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m 2 ) and Triple T with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma (An Interim Analysis).

Thalidomide-Dexamethasone Versus Melphalan-Prednisolone as First Line Treatment in Elderly Patients with Multiple Myeloma: An Interim Analysis.

Elevated Serum Thymidine Kinase Levels Identify a Subgroup at High Risk of Disease Progression in Early, Nonsmoldering Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only